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INTRODUCTION
Sleep-disordered breathing (SDB) in childhood describes a spec-
trum of abnormalities ranging from primary snoring to obstruc-
tive sleep apnea syndrome (OSAS). Chronic sleep-related air-
way obstruction results in repetitive hypoxemia and sleep dis-
turbance that can cause neurocognitive disturbance, growth fail-
ure, and cor pulmonale (1). 
  The most common symptoms associated with this disorder 
are habitual snoring, difficulty breathing, witnessed apneas, rest-
less sleep, and daytime neurobehavioral problems (2). Frequent 
snoring was observed at 3.2% and occasionally at 16.7% in an 
epidemiological study (3). Sleep apnea has been reported at be-
tween 1% and 3% of children and occurs most frequently in 
children between 2 and 6 years old (4). Pediatric SDB is usually 
managed with adenotonsillectomy which needs general anes-
thesia and sometimes is associated with complication including 
bleeding and perioperative respiratory compromise. As adjunc-
tive treatments, nonsurgical alternatives for reduction of adenoid 
size are limited. However, recent studies showed that topical na-
sal corticosteroid spray reduced adenoid size and improved symp-
toms of nasal airway obstruction and OSAS (1, 2). Topical nasal 
corticosteroid spray is considered to be the first line treatment 
for allergic rhinitis which is also associated with sleep disturbance 
through nasal obstruction, enlargement of tonsils and adenoids, 
and an elongated face (5, 6). However, there are few results which 
show its effect in the SDB children irrespective of allergic rhini-
tis, sinusitis and body weight.
  This study was aimed to evaluate the efficacy of short term 
Objectives. To evaluate efficacy of short term intranasal corticosteroid (mometasone furoate) treatment in pediatric sleep-
disordered breathing (SDB) patients.
Methods. A prospective, observational study was done. A total of 41 children (2-11 years old) were enrolled into this study. 
All patients received 4-weeks course of mometasone furoate 100 μg/day treatment. They were evaluated at pretreat-
ment and immediately after treatment with obstructive sleep apnea (OSA)-18 quality of life survey and lateral neck 
X-ray. Also, the assessment of each patients included history, skin prick test or CAP test, and sinus radiography. We 
compared the OSA-18 survey score and adenoidal-nasopharyngeal (AN) ratio between before and after treatment.
Results. Total OSA-18 score and AN ratio decreased significantly after treatment regardless of allergy, sinusitis, and obesity 
(P=0.003, P=0.006). There was no complication after treatment of mometasone furoate.
Conclusion. Pediatric SDB patients with adenoid hypertrophy could be effectively treated with 4-weeks course of mometa-
sone furoate. Allergy, obesity, and sinusitis did not affect on the result of treatment. 
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mometasone furoate in pediatric SDB patients with parental 
questionnaire (obstructive sleep apnea-18, OSA-18) and lateral 
neck X-ray and to identify the effect of allergy, sinusitis, and 
obesity on treatment result.
MATERIALS AND METHODS
Study population
This prospective, observational study was approved by the Insti-
tutional Review Board of the Samsung Medical Center. Forty 
one (32 males, 9 females), two to eleven year-old children, who 
visited otolaryngology clinic due to sleep disordered breathing 
were recruited between March 2006–July 2007, based on the 
following inclusion criteria: 1) history of habitual snoring for the 
last 3 months or longer, and 2) adenoid hypertrophy confirmed 
with simple X-ray findings or endoscopic examination by oto-
laryngologist. Children were excluded from the study if they 
met any of the exclusion criteria: 1) presence of symptoms of 
acute respiratory infection; 2) use of nasal or systemic cortico-
steroid or antibiotics within 4 weeks prior to the study; 3) prior 
tonsil or adenoid surgery; and 4) a history of craniofacial, neu-
romuscular, or genetic disorders. 
Diagnostic criteria and method
Informed consent for participation in this study was obtained 
from the parent or legal guardian of each child enrolled. Initial 
assessment of each patient upon entering the study included the 
following: history and physical examination (including body 
weight and height), parental questionnaire (OSA-18), sinus X-
ray, adenoid X-ray, and skin prick test or Pharmacia CAP sys-
tem for detecting allergy. Allergic rhinitis was diagnosed in case 
that each child complaining typical allergic symptoms showed 
positive result in allergic test.
  We checked paranasal sinus X-ray for detecting the presence 
of sinusitis and categorized into three group: no evidence of si-
nusitis, unilateral haziness, and bilateral haziness. For the evalu-
ation of obesity, body weight was checked and we judged each 
child for obesity with their body weight, height, and age accord-
ing to Korean pediatric standard growth curve. We regarded each 
child as obese in case that body weight belong to upper 10 per-
centile according to growth curve. Body weight was checked at 
before and after treatment for identification of bias according to 
change of body weight. All patients received 4 weeks course of 
single intranasal administration in each nostril with mometa-
sone furoate (100 μg). After 4 weeks course of therapy, all pa-
tients were re-assessed to evaluate the efficacy of treatment.
Outcome measures
The primary outcome was measured with the OSA-18 survey 
(Table 1), a valid and reliable discriminative quality of life (QOL) 
measure for children with varying levels of SDB (7, 8). The 
OSA-18 has been previously shown to possess satisfactory test-
retest reliability and internal consistency (7). The survey consists 
Table 1. Parental questionnaire (OSA-18) for sleep disordered breathing
Evaluation of sleep-disordered breathing None All the time
Sleep disturbance (S) 1 2 3 4 5 6 7
Loud snoring? 1 2 3 4 5 6 7
Breath holding spells or pause in breathing at night? 1 2 3 4 5 6 7
Chocking or gasping sounds while a sleep? 1 2 3 4 5 6 7
Restless sleep or frequent awakening from sleep? 1 2 3 4 5 6 7
Physical suffering (P) 1 2 3 4 5 6 7
Mouth breathing because of nasal obstruction 1 2 3 4 5 6 7
Frequent colds or upper respiratory obstruction? 1 2 3 4 5 6 7
Nasal discharge or runny nose? 1 2 3 4 5 6 7
Difficulty in swallowing foods? 1 2 3 4 5 6 7
Emotional distress (E) 1 2 3 4 5 6 7
Mood swings or temper tantrums? 1 2 3 4 5 6 7
Aggressive or hyperactive behavior? 1 2 3 4 5 6 7
Discipline problems? 1 2 3 4 5 6 7
Daytime problems (D) 1 2 3 4 5 6 7
Excessive daytime drowsiness or sleepiness? 1 2 3 4 5 6 7
Poor attention span or concentration? 1 2 3 4 5 6 7
Difficulty getting out of bed in the morning? 1 2 3 4 5 6 7
Caregiver congress (C) 1 2 3 4 5 6 7
Caused you to worry about child’s general health? 1 2 3 4 5 6 7
Created concern that child is not getting enough air? 1 2 3 4 5 6 7
Interfered with your ability to perform daily activities? 1 2 3 4 5 6 7
Made you frustrated? 1 2 3 4 5 6 7
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of 18 items grouped into 5 domains: sleep disturbance (4 items), 
physical suffering (4 items), emotional distress (3 items), day-
time problems (3 items), and caregiver concerns (4 items). Items 
are scored on a 7-point ordinal scale and have excellent test-re-
test reliability. 
  After completing questionnaire, OSA-18, they were evaluated 
for measuring adenoidal-nasopharyngeal (AN) ratios by using 
lateral radiographs of nasopharynx. Lateral radiographs of the 
nasopharynx were exposed with the patient in the erect posi-
tion and the head fixed with a wall-mounted cephalostat and 
oriented with the Frankfort horizontal plane. The exposures were 
made with 70 kV, and the exposure time varied between 0.4 
and 0.6 depending on the age of the children. For each of the 
radiographs, the AN ratio was computed according to the meth-
od of Fujioka et al. (9) (Fig. 1). 
Statistics
The AN ratio was obtained by dividing the measurement for A 
by the value for N. A commercially available statistical program 
(SPSS ver. 11.5, SPSS Inc, Chicago, IL, USA) was used to per-
form the statistical analysis. Statistical comparisons of changes 
in OSA-18 score between before and after topical intranasal 
mometasone furoate treatment employed Wilcoxon signed rank 
test. A paired t-test was used for comparison of changes in AN 
ratio and body weight. Spearmann rank correlation analysis was 
employed to analyze the correlation between change in OSA-18 
score and change in AN ratio. Mann-Whitney U-test was used to 
analyze the effect of allergy, obesity and sinusitis on the change 
of OSA-18 score. A P-value of less than 0.05 was considered 
statistically significant. 
RESULTS
Table 2 summarizes the demographic data including the patient’s 
age, sex, body weights, and history of allergy. All 41 children 
Table 2. Characteristics of  patients
Characteristics Values
No. of subjects 41
Mean age (year) 6.4 (2-11)
Sex (male) 31 (75.6%)
Obesity 8 among 20 patients*
History of allergy 17 among 37 patients
†
Presence of sinusitis No haziness (17), unilateral (5), and bilateral (19)
*20 of 41 children were checked body weight and height. We re-
garded each child as obese in case that body weight belongs to 
upper 10 percentile according to growth curve. 
†37 of 41 children 
were checked for allergy.
Table 3. Parental questionnaire (OSA-18) results before and after in-
tranasal corticosteroid treatment
Before treatment After treatment P-value
Sleep disturbance 13.58±4.82 10.85±5.46 <0.001
Loud snoring 5.53 3.90 <0.001
Breath holding /pause 2.87 2.26 0.004
Choking or gasping 2.12 2.09 NS*
Fragmented sleep 3.04 2.58 0.034
Physical symptom 15.85±4.78 13.19±5.00 0.001
Mouth breathing 5.24 4.07 0.001
Frequent URI 4.31 3.51 0.004
Rhinorrhea 4.04 3.48 0.044
Dysphagia 2.24 2.12 NS
Emotional distress 8.39±4.29 8.00±4,18 NS
Mood swings or tantrums  2.97 3.00 NS
Aggression/hyperactive 2.82 2.56 NS
Discipline problems 2.58 2.43 NS
Daytime function 8.85±3.76 8.53±3.64 NS
Daytime drowsiness 2.39 2.41 NS
Poor attention span 3.04 2.82 NS
Difficulty awaking 3.41 3.29 NS
Caregiver concerns 12.19±6.01 10.68±4.80 NS
Worried  over child health 4.00 3.73 NS
Concerned not enough air 3.82 3.14 0.017
Missed activities 2.21 1.97 NS
Frustration 2.14 1.82 NS
Total 58.87±13.26 51.26±12.87 0.003
*No statistically significant difference.
URI: upper respiratory infection; OSA-18: obstructive sleep ap-
nea-18.
Fig. 1.  Method of assessing adenoid enlargement on lateral neck 
radiography. In this method the adenoidal measurement (A) repre-
sents the distance from the point of maximal convexity of the ade-
noid shadow to a line along the anterior margin of the basiocciput. 
The nasopharyngeal measurement (N) is the distance between the 
posterior border of the hard palate and the antero-inferior edge of 
the sphenobasioccipital synchondrosis.
A
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completed the 4-weeks course of intranasal mometasone fu-
roate treatment. Compliance with daily nasal spray was compa-
rable and there was no significant side effect such as dry nose 
and epistaxis.
  The changes of OSA-18 survey score after treatment are shown 
in Table 3. Sleep disturbance and physical suffering were the 
highest rated domains, followed by caregiver concerns, daytime 
problems, and emotional distress. 
  There was significant reduction in score of sleep disturbance 
domain (P<0.001) and physical symptom domain (P=0.001) 
after treatment. Also, total OSA-18 score decreased significantly 
(P=0.003) after the treatment (Fig. 2). Among 41 patients, 37 
children were tested for allergy and 17 patients were proved to 
have allergic rhinitis based on their symptom and allergy test. 
And we could obtain the information of body weight and height 
in 20 children, and 8 children were proved to be obese. But, 
presence of allergy (P=0.065) and obesity (P=0.851) didn’t af-
fect the effect of nasal steroid on total OSA-18 score. There was 
no significant change in body weight between before and after 
treatment (P=0.954). 
  Sinus X-ray was checked in all children and sinusitis were de-
tected in 24 children. 19 children showed bilateral haziness of 
sinus on X-ray and 5 children showed unilateral haziness. Change 
in OSA-18 score showed no significant difference according to 
presence of sinusitis (P=0.488).
  The mean AN ratio was 0.63±0.11 before the treatment and 
0.59±0.12 after the treatment. There was a statistically signifi-
cant difference (P=0.006) between before and after treatment 
(Fig. 3). There was no significant correlation between the chang-
es of AN ratio and improvement of symptom score (P=0.858).
DISCUSSION
This prospective, observational study shows a significant improve-
ment in both mean OSA-18 survey score and adenoidal-naso-
pharyngeal ratio in children with sleep disordered breathing af-
ter 4-weeks trial of intranasal monetasone furoate. Among OSA-
18 items, loud snoring, breath holding, fragmented sleep, mouth 
breathing, frequent URI, and rhinorrhea were improved signifi-
cantly. The mean OSA-18 survey score improved in 27 of 41 
children (65.8%) treated with monetasone furonate. Physical 
suffering (mean score, 3.96) and sleep disturbance (mean score, 
3.40) were the highest rated domains, and this result was identi-
cal to other study (4).
  Among several commercially available steroid nasal sprays, 
we selected mometasone furoate for this study. This spray had 
been reported previously not to cause any adverse effect on na-
sal mucosa on long term use (10) and it has no effect on growth 
and hypothalamic-pituitary-adrenal axis. Above all things (11, 
12), the systemic availability of the drug after topical adminis-
tration is lower than that of other steroids (13).
  In 2001, Brouilette et al. (1) tested the efficacy of another in-
tranasal steroid treatment for OSAS. In this trial they investigat-
ed the effect of fluticasone propionate nasal spray versus place-
bo for 25 children suffering from OSAS, with results of poly-
somnography. In this study 69% of children who received fluti-
casone showed improvement in symptom score.
  Recently Berlucchi et al. (14) assessed the efficacy of mometa-
sone furonate in treatment of adenoid hypertrophy after 40 days 
course of treatment. Of patients enrolled, 77.7% of children 
showed symptomatic improvement, that is somewhat superior 
to our result. But, considering the relatively short course of 
treatment of our study, our result dose not seems to much dif-
ferent to that of previous study.
  We used lateral neck X-ray for assessment of adenoid hyper-
trophy, and this method was widely used for decades. Fujioka et 
al. (9) in 1979 described AN ratio as an indicator of adenoidal 
size, and this method had been adopted in many other studies. 
Cohen et al. (15) in 1992 reported usefulness of lateral cervical 
* *
*
Fig. 2. Comparison of symptom score between pre and post-4weeks 
course of topical steroid treatment. S: sleep disturbance; P: physical 
suffering; E: emotional distress; D: daytime problems; C: caregiver 
concerns. *P<0.05. 
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Fig. 3. Comparison of adenoid-nasopharyngeal (AN) ratio between 
pre and post-4weeks course of topical steroid treatment. *P<0.05.
*
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radiographs in evaluation of adenoid size, and Major et al. (16) 
in 2006 systematically reviewed lateral cephalometric diagnosis 
in adenoid hypertrophy, and proved that the results of lateral 
neck X-ray showed good correlation with actual adenoid size.
  Acoustic rhinometry have been known as useful tool in evalu-
ating nasopharyngeal cross-sectional area and volume after ade-
noidectomy (17, 18). But short term use of mometasone nasal 
spray couldn’t make so much reduction of adenoid size compar-
ing with adenoidectomy. Considering the effect of nasal cycle 
on acoustic rhinometry and reduction of adenoid size after ap-
plication of intransal spray, we didn’t employ acoustic rhinome-
try as a tool to evaluate efficacy of short term nasal steroid spry 
for pediatric sleep disorderd breathing.
  In our study, 22 of 31 children (71%) who had tested with 
lateral neck radiography, showed decreased AN ratio after 4 
weeks course of treatment (P=0.006). Demain and Goetz (19) 
in 1995 reported a study of standard dose aqueous nasal beclo-
methasone in treatment of adenoid hypertrophy. All Adenoid 
size was decreased in all enrolled patients after 8 weeks treat-
ment and mean reduction in AN ratio was 29%. Cengel and 
Akyol (20) in 2006 studied change of adenoid size after 6 weeks 
course of intransal mometasone furonate treatment. 67.2% of 
enrolled children showed reduction of adenoid size after treat-
ment. However there has been no proven mechanism about 
shrinkage of adenoid. Existence of inflammation had been 
proved in mucosal surface at soft plate in OSAS patients (21, 
22). We think that this type of inflammation might exist in cov-
ering mucosa of adenoid which locates at narrowest area of up-
per airway. For this reason, application of topical steroid for 4 
weeks might reduce the inflammation of covering mucosa of 
adenoid. Therefore, application of intransal steroid can be effec-
tive treatment option for reducing adenoid size.
  We chose OSA-18 as the measuring tool for assessing the effi-
cacy of intranasal steroid. In 2000, Franco et al. (23) proposed 
OSA-18 as a practical mean of office-based determination of 
quality-of-life impact for obstructive sleep apnea syndrome in 
children. In 2005, Michell and Kelly (24) used OSA-18 as indi-
cator for treatment response after adenotonsillectomy in SDB 
children and mentioned that it was so useful. OSA-18 is com-
posed of easily applicable 18 questions and has relatively high 
reproducibility (4), and it is known that OSA-18 shows good 
correlation with respiratory disturbance index (RDI) (25).
  In our study, parents or caregivers could easily carry out the 
questionnaire and it takes only few minutes to fill up the form. 
For this reason, we thought that OSA-18 can be excellent tool 
for evaluating SDB children after treatment in office-based clin-
ics or other clinics without polysomnography (PSG). Moreover, 
in the case of tertiary care clinics with PSG, OSA-18 can have a 
additional role in children not suitable for PSG.
  There are a few options for evaluating the adenoid size in pe-
diatric SDB patients. Among them lateral neck radiography and 
direct video rhinoscopy has been used widely. Mlynarek et al. 
(25) in 2004 reported that direct video rhinoscopy is better cor-
related to the severity of symptoms than are values obtained by 
lateral neck radiography. But fiberoptic examination of child’s 
nasopharynx can be challenging and might not be suitable for 
all patients. In some children it is impossible to exam nasophar-
ynx due to patient’s noncooperation (26). For this reason we se-
lected lateral neck radiography for assessing adenoid size. But 
we could not get data from all enrolled children. Some patients 
refused to let their children be exposed radiation in spite of 
harmless dose.
  As the result of our study, allergic rhinitis and sinusitis had no 
influence on degree of change in adenoid size and in OSA-18 
score. According to other report, adenoid size decreased signifi-
cantly after intranasal steroid and there was notable difference 
in improvement after treatment according to allergy status (27). 
But there are not so many reports about effect of allergy on effi-
cacy of intranasal steroid in pediatric SDB patients, so further 
research is required with large sample size.
  We assumed that improvement in quality of life of SDB chil-
dren is due to not only decreased AN ratio but also other factors 
such as increase nasal airway patency. Considering this result, 
intranasal steroid can be used in SDB children regardless of al-
lergic status or sinusitis.
  There are some limitations to this study. We could not have a 
control group due to lack of consent. At early period of this study, 
we wanted to have control group using placebo. But most par-
ents and caregivers refused to participate in our study because 
of using placebo. The other limitation is that we didn’t confirm 
the increased nasal airway patency with objective tool. In gener-
al, acoustric rhinometry has been used as popular tool for as-
sessing nasal airway. But most cohorts of our study were under 
5 years old, so it was impossible to get patient’s cooperation 
during acoustic rhinometry.
  In conclusion, We believe that 4-weeks course of intranasal 
steroid (mometasone furoate) can be a effective treatment op-
tion in pediatric SDB patients without significant complications. 
And this treatment works effectively regardless of allergic status, 
sinusitis, and obesity.
  Future placebo controlled study will be required to ascertain 
the effect of short term steroid use for pediatric sleep disordered 
breathing.
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